KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $296.8 million.

  • CRISPR Therapeutics AG's Cash from Financing Activities rose 297848.55% to $296.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $326.5 million, marking a year-over-year decrease of 778.4%. This contributed to the annual value of $332.0 million for FY2024, which is 42978.42% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Cash from Financing Activities stood at $296.8 million, which was up 297848.55% from $2.3 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Cash from Financing Activities' 5-year high stood at $305.9 million during Q1 2024, with a 5-year trough of -$466000.0 in Q2 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's median Cash from Financing Activities value was $10.4 million (recorded in 2022), while the average stood at $52.3 million.
  • In the last 5 years, CRISPR Therapeutics AG's Cash from Financing Activities surged by 1986386.93% in 2021 and then tumbled by 10277.96% in 2024.
  • CRISPR Therapeutics AG's Cash from Financing Activities (Quarter) stood at $6.3 million in 2021, then plummeted by 60.66% to $2.5 million in 2022, then surged by 1471.39% to $38.9 million in 2023, then plummeted by 56.66% to $16.9 million in 2024, then surged by 1658.51% to $296.8 million in 2025.
  • Its last three reported values are $296.8 million in Q3 2025, $2.3 million for Q2 2025, and $10.6 million during Q1 2025.